Pharmacological inhibition of AIMP2 aggregation attenuates ?-synuclein aggregation and toxicity in Parkinson?s disease
Citations

WEB OF SCIENCE

5
Citations

SCOPUS

5

초록

The aggregation of aminoacyl transfer RNA synthetase complex-interacting multifunctional protein-2 (AIMP2) accelerates alpha-synuclein aggregation via direct interaction, leading to enhanced dopaminergic neurotoxicity in Parkinson's disease (PD). Thus, it would be beneficial to prevent AIMP2 aggregation to suppress alpha-synucleinopathy in PD. In this study, we screened small compounds that could inhibit the in vitro aggregation of AIMP2 using a 1909 small-compound library. The AIMP2 inhibitors (SAI-04, 06, and 08) with the most effective inhibition of AIMP2 aggregation bind to AIMP2, disaggregate the pre-formed AIMP2 aggregates, and prevented AIMP2/alpha-synuclein coaggregation and cytotoxicity in SH-SY5Y cells. Moreover, AIMP2 inhibitors prevented alpha-synuclein preformed fibril (PFF)-induced pathological AIMP2 aggregation in both mouse cortical and embryonic stem cell-derived human dopaminergic neurons, thereby blocking PFF-induced alpha-synuclein aggregation and neurotoxicity. Collectively, our results suggest that the use of brain-permeable AIMP2 aggregation inhibitors may serve as an effective therapeutic strategy for alpha-synucleinopathy in PD.

키워드

AIMP2 aggregates?-synucleinopathyAIMP2 inhibitorsHuman dopaminergic neuronParkinson?s diseaseALPHA-SYNUCLEINLEWY BODYFIBRILS1ST
제목
Pharmacological inhibition of AIMP2 aggregation attenuates ?-synuclein aggregation and toxicity in Parkinson?s disease
저자
Shin, Jeong-YongLee, BinaHam, SangwooKim, Ji HunKim, HyojungKim, HeejeongJo, Min GiKim, Hye JungPark, Sang WonKweon, Hee-SeokKim, Yong JunYun, Seung PilLee, Yunjong
DOI
10.1016/j.biopha.2022.113908
발행일
2022-12
유형
Article
저널명
Biomedicine and Pharmacotherapy
156